Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENLV NASDAQ:HRTX NASDAQ:KRRO NASDAQ:LITS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.75+0.9%$0.97$0.66▼$2.10$178.04M1.49518,477 shs162,610 shsHRTXHeron Therapeutics$0.98+2.7%$0.97$0.74▼$2.30$185.81M1.71.97 million shs1.81 million shsKRROKorro Bio$11.12-3.0%$12.41$5.20▼$55.89$160.78M3.07206,058 shs65,231 shsLITSLite Strategy$1.23-1.2%$1.16$0.95▼$9.00$44.54M0.25351,593 shs204,435 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics-3.48%-8.92%-22.70%-35.37%-27.14%HRTXHeron Therapeutics-21.05%-24.78%+11.99%-24.78%-54.73%KRROKorro Bio-4.90%-15.55%-9.62%-5.60%-26.35%LITSLite Strategy+1.64%+9.73%+6.90%+20.39%+123,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$0.75+0.9%$0.97$0.66▼$2.10$178.04M1.49518,477 shs162,610 shsHRTXHeron Therapeutics$0.98+2.7%$0.97$0.74▼$2.30$185.81M1.71.97 million shs1.81 million shsKRROKorro Bio$11.12-3.0%$12.41$5.20▼$55.89$160.78M3.07206,058 shs65,231 shsLITSLite Strategy$1.23-1.2%$1.16$0.95▼$9.00$44.54M0.25351,593 shs204,435 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics-3.48%-8.92%-22.70%-35.37%-27.14%HRTXHeron Therapeutics-21.05%-24.78%+11.99%-24.78%-54.73%KRROKorro Bio-4.90%-15.55%-9.62%-5.60%-26.35%LITSLite Strategy+1.64%+9.73%+6.90%+20.39%+123,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics 2.00Hold$16.502,100.00% UpsideHRTXHeron Therapeutics 2.20Hold$4.50358.72% UpsideKRROKorro Bio 2.73Moderate Buy$37.29235.42% UpsideLITSLite Strategy 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LITS, ENLV, KRRO, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026KRROKorro Bio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026KRROKorro Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026ENLVEnlivex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.003/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/13/2026KRROKorro Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $22.003/13/2026KRROKorro Bio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$23.002/26/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell2/18/2026KRROKorro Bio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$18.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AHRTXHeron Therapeutics$154.90M1.19N/AN/A$0.07 per share14.01KRROKorro Bio$6.39M25.08N/AN/A$5.46 per share2.04LITSLite Strategy$65.30M0.68$6.13 per share0.20$4.96 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/AHRTXHeron Therapeutics-$20.19M-$0.13N/A8.18N/A-13.04%N/A-4.62%N/AKRROKorro Bio-$117.26M-$11.67N/AN/AN/A-1,834.48%-128.21%-74.75%N/ALITSLite Strategy-$15.94M-$1.33N/AN/AN/AN/A-68.86%-67.48%N/ALatest LITS, ENLV, KRRO, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/7/2026Q1 2026KRROKorro Bio-$1.60-$1.69-$0.09-$1.69$0.76 millionN/A3/12/2026Q4 2025KRROKorro Bio-$1.93-$5.32-$3.39-$5.32$0.43 million$1.29 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 million2/17/2026Q2 2026LITSLite StrategyN/A-$0.82N/A-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A193.24193.24HRTXHeron Therapeutics10.592.481.51KRROKorro BioN/A6.906.90LITSLite StrategyN/A10.0410.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%HRTXHeron Therapeutics80.01%KRROKorro Bio13.18%LITSLite Strategy52.38%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%HRTXHeron Therapeutics5.86%KRROKorro Bio4.60%LITSLite Strategy1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableKRROKorro Bio7014.42 million13.76 millionNo DataLITSLite Strategy10036.36 million35.78 millionN/ALITS, ENLV, KRRO, and HRTX HeadlinesRecent News About These CompaniesIs Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?April 25, 2026 | finance.yahoo.comLite Strategy Inc.April 18, 2026 | barrons.comLite Strategy IncApril 8, 2026 | cnn.comLite Strategy, Inc. Common Stock (LITS) Institutional HoldingsApril 6, 2026 | nasdaq.comLite Strategy Inc LITSMarch 26, 2026 | morningstar.comMLite Strategy, Inc. Reports Second Quarter Fiscal 2026 Financial Results and Launches Active Treasury Management InitiativesFebruary 17, 2026 | quiverquant.comQLite Strategy Reports Fiscal 2026 Second Quarter ResultsFebruary 17, 2026 | globenewswire.comLiTHOS Announces Board and Management ChangeJanuary 14, 2026 | newsfilecorp.comNJames Flynn Acquires 70,000 Shares of Lite Strategy (NASDAQ:LITS) StockDecember 23, 2025 | insidertrades.comFive Days, Zero Inflows: Litecoin ETF Struggles to Break $7.44 MillionNovember 25, 2025 | finance.yahoo.comLite Strategy names acting CEO Justin File to role on a permanent basisNovember 20, 2025 | msn.comLite Strategy Reports First Quarter Fiscal Year 2026 Results, Highlights Successful Launch of $100 Million Litecoin Treasury Strategy and Movement Into Active Capital Market ...November 18, 2025 | dailyhodl.comDLite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market OperationsNovember 17, 2025 | markets.businessinsider.comLite Strategy $25M Share RepurchaseOctober 30, 2025 | ventureburn.comVLite Strategy announces $25M share repurchase programOctober 29, 2025 | msn.comLite Strategy stock surges after announcing $25 million share buybackOctober 29, 2025 | in.investing.comLite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market OperationsOctober 29, 2025 | markets.businessinsider.comLite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026October 16, 2025 | markets.businessinsider.comLite Strategy, Inc. Celebrates 14 Years of Litecoin as It Adopts LTC as Primary Reserve AssetOctober 16, 2025 | quiverquant.comQLite Strategy, Inc. (LITS)October 14, 2025 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLITS, ENLV, KRRO, and HRTX Company DescriptionsEnlivex Therapeutics NASDAQ:ENLV$0.75 +0.01 (+0.91%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Heron Therapeutics NASDAQ:HRTX$0.98 +0.03 (+2.69%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Korro Bio NASDAQ:KRRO$11.12 -0.34 (-3.00%) As of 02:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Lite Strategy NASDAQ:LITS$1.23 -0.02 (-1.21%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas On Holdings Sets Up for Marathon Rally: New Highs Are Coming Shake Shack Stock Gets Shaken After Earnings Miss Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? MP Materials Is Quietly Building a Rare Earth Powerhouse The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000 Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
